MRX34, Mirna Therapeutics' mimic of the naturally occurring miR-34 tumor suppressor, is safe, effective and well-tolerated in animals, according to results presented at the Keystone Conference on Noncoding RNAs in Development and Cancer, and is expected to move into clinical trials during the first half of this year. The trial will involve people with advanced cancers of the liver. MRX34 is delivered in a liposome, which should extend the life of the drug. Last year, Mirna raised $34.5 million from its backers to support the development of MRX34 through human proof-of-concept studies. Press release (pdf)